{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T22:33:37Z","timestamp":1784154817831,"version":"3.55.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009210","name":"Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jval.2020.07.013","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T18:54:03Z","timestamp":1603738443000},"page":"158-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Economic Evaluation in Opioid Modeling: Systematic Review"],"prefix":"10.1016","volume":"24","author":[{"given":"Elizabeth","family":"Beaulieu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"DiGennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Stringfellow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz","family":"Hyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Cerd\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Keyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad S.","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2020.07.013_bib2","series-title":"CDC Director\u2019s Media Statement on U.S. Life Expectancy [press release]; 2018","year":"2018"},{"key":"10.1016\/j.jval.2020.07.013_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and Opioid-Involved Overdose Deaths \u2014 United States, 2017\u20132018","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jval.2020.07.013_bib4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jval.2020.07.013_bib5","article-title":"Results from the 2017 National Survey on Drug Use and Health: Detailed Tables","year":"2018","journal-title":"US Health and Human Services"},{"key":"10.1016\/j.jval.2020.07.013_bib6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12961-020-00596-8","article-title":"The opioid crisis: a contextual, social-ecological framework","volume":"18","author":"Jalali","year":"2020","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.jval.2020.07.013_bib7","series-title":"Economy at Least $631 Billion Over Four Years: Society of Actuaries\u2019 Analysis [press release]","year":"2019"},{"key":"10.1016\/j.jval.2020.07.013_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.drugalcdep.2017.05.001","article-title":"Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids\u2014conception and maturation","volume":"178","author":"McDonald","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.jval.2020.07.013_bib9","series-title":"Medications for Opioid Use Disorder Save Lives","year":"2019"},{"issue":"168","key":"10.1016\/j.jval.2020.07.013_bib10","article-title":"Economic evaluation of implementation strategies in health care","volume":"9","author":"Hoomans","year":"2014","journal-title":"Implementation Sci"},{"issue":"4","key":"10.1016\/j.jval.2020.07.013_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0272989X17697019","article-title":"Extrapolation of survival data in cost-effectiveness analyses: the need for causal clarity","volume":"37","author":"Hawkins","year":"2017","journal-title":"Med Decis Making"},{"issue":"31","key":"10.1016\/j.jval.2020.07.013_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/oxfordjournals.jncimonographs.a003471","article-title":"Public health policy and cost-effectiveness analysis","volume":"2003","author":"Goldie","year":"2003","journal-title":"JNCI Monographs"},{"issue":"1 suppl","key":"10.1016\/j.jval.2020.07.013_bib13","doi-asserted-by":"crossref","first-page":"74S","DOI":"10.1177\/1090198113492767","article-title":"Modeling the impact of simulated educational interventions on the use and abuse of pharmaceutical opioids in the United States: a report on initial efforts","volume":"40","author":"Wakeland","year":"2013","journal-title":"Health Educ Behav"},{"issue":"6","key":"10.1016\/j.jval.2020.07.013_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3109\/00952990.2015.1043435","article-title":"Dynamic model of nonmedical opioid use trajectories and potential policy interventions","volume":"41","author":"Wakeland","year":"2015","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"10.1016\/j.jval.2020.07.013_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7621","article-title":"Prevention of prescription opioid misuse and projected overdose deaths in the United States","volume":"2","author":"Chen","year":"2019","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.jval.2020.07.013_bib16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2105\/AJPH.2018.304590","article-title":"Modeling health benefits and harms of public policy responses to the US opioid epidemic","volume":"108","author":"Pitt","year":"2018","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jval.2020.07.013_bib17","article-title":"Evidence of modeling impact in development of policies for controlling the opioid epidemic and improving public health: a scoping review","volume":"13","author":"Sharareh","year":"2019","journal-title":"Subst Abuse"},{"key":"10.1016\/j.jval.2020.07.013_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12961-020-00598-6","article-title":"The opioid crisis: need for systems science research","volume":"18","author":"Jalali","year":"2020","journal-title":"Health Res Policy Syst"},{"issue":"5","key":"10.1016\/j.jval.2020.07.013_bib19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00019053-200826050-00003","article-title":"Economic evaluation of interventions to treat opiate dependence: a review of the evidence","volume":"26","author":"Doran","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2020.07.013_bib20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13722-017-0071-3","article-title":"A\u00a0systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence","volume":"12","author":"Chetty","year":"2017","journal-title":"Addict Sci Clin Pract"},{"issue":"9","key":"10.1016\/j.jval.2020.07.013_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","article-title":"Economic evaluations of opioid use disorder interventions","volume":"34","author":"Murphy","year":"2016","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.jval.2020.07.013_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cplx.10040","article-title":"Drugmart: heroin epidemics as complex adaptive systems","volume":"7","author":"Agar","year":"2002","journal-title":"Complexity"},{"key":"10.1016\/j.jval.2020.07.013_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev-psych-010418-102803","article-title":"How to do a systematic review: a best practice guide for conducting and reporting narrative reviews, meta-analyses, and meta-syntheses","volume":"70","author":"Siddaway","year":"2019","journal-title":"Annu Rev Psychol"},{"key":"10.1016\/j.jval.2020.07.013_bib24","article-title":"Joanna Briggs Institute Reviewers\u2019 Manual: 2014 edition","year":"2014","journal-title":"The Joanna Briggs Institute"},{"key":"10.1016\/j.jval.2020.07.013_bib25","series-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"1987"},{"issue":"1","key":"10.1016\/j.jval.2020.07.013_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-018-0751-1","article-title":"Health economic evaluations of non-pharmacological interventions for persons with dementia and their informal caregivers: a systematic review","volume":"18","author":"Nickel","year":"2018","journal-title":"BMC Geriatr"},{"issue":"5","key":"10.1016\/j.jval.2020.07.013_bib27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/21645515.2015.1131369","article-title":"Economic evaluation of pediatric influenza immunization program compared with other pediatric immunization programs: a systematic review","volume":"12","author":"Gibson","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.jval.2020.07.013_bib28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10198-002-0100-2","article-title":"Developing a scoring system to quality assess economic evaluations","volume":"3","author":"Gonzalez-Perez","year":"2002","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2020.07.013_bib29","series-title":"Deploying an interactive machine learning system in an evidence-based practice center: abstrackr","author":"Wallace","year":"2012"},{"issue":"7","key":"10.1016\/j.jval.2020.07.013_bib30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.2105\/AJPH.90.7.1100","article-title":"HIV transmission and the cost effectiveness of methadone maintenance","volume":"90","author":"Zaric","year":"2000","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.jval.2020.07.013_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000423","article-title":"Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine","volume":"8","author":"Alistar","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.jval.2020.07.013_bib32","series-title":"Cost-Effectiveness in Health and Medicine","author":"Neumann","year":"2016"},{"issue":"2","key":"10.1016\/j.jval.2020.07.013_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jval.2017.12.006","article-title":"An overview of value, perspective, and decision context\u2014a health economics approach: an ISPOR special task force report [2]","volume":"21","author":"Garrison","year":"2018","journal-title":"Value in Health"},{"issue":"10","key":"10.1016\/j.jval.2020.07.013_bib34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jval.2020.07.013_bib35","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5055\/jom.2017.0398","article-title":"Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients","volume":"13","author":"Yenikomshian","year":"2017","journal-title":"J\u00a0Opioid Manag"},{"issue":"8","key":"10.1016\/j.jval.2020.07.013_bib36","first-page":"600","article-title":"Budgetary impact of the utilization of buprenorphine\/naloxone sublingual film and tablet for Medicaid in the United States","volume":"18","author":"Asche","year":"2015","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.jval.2020.07.013_bib37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1360-0443.1999.9444793.x","article-title":"The cost-effectiveness of methadone maintenance as a health care intervention","volume":"94","author":"Barnett","year":"1999","journal-title":"Addiction"},{"issue":"9","key":"10.1016\/j.jval.2020.07.013_bib38","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1046\/j.1360-0443.2001.96912676.x","article-title":"The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States","volume":"96","author":"Barnett","year":"2001","journal-title":"Addiction"},{"issue":"8","key":"10.1016\/j.jval.2020.07.013_bib39","first-page":"893","article-title":"Cost-effectiveness of subdermal implantable buprenorphine versus sublingual buprenorphine to treat opioid use disorder","volume":"20","author":"Carter","year":"2017","journal-title":"J\u00a0Med Econ"},{"issue":"7","key":"10.1016\/j.jval.2020.07.013_bib40","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1465-3362.2012.00472.x","article-title":"Subsidising patient dispensing fees: the cost of injecting equity into the opioid pharmacotherapy maintenance system","volume":"31","author":"Chalmers","year":"2012","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"10.1016\/j.jval.2020.07.013_bib41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/08897077.2015.1010031","article-title":"Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence","volume":"36","author":"Jackson","year":"2015","journal-title":"Subst Abus"},{"issue":"1","key":"10.1016\/j.jval.2020.07.013_bib42","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/15360288.2015.1135847","article-title":"Office-based buprenorphine versus clinic-based methadone: a cost-effectiveness analysis","volume":"30","author":"King","year":"2016","journal-title":"J\u00a0Pain Palliat Care Pharmacother"},{"issue":"1","key":"10.1016\/j.jval.2020.07.013_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M17-0611","article-title":"Cost-effectiveness of publicly funded treatment of opioid use disorder in California","volume":"168","author":"Krebs","year":"2018","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jval.2020.07.013_bib44","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1360-0443.2004.00728.x","article-title":"Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification","volume":"99","author":"Masson","year":"2004","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jval.2020.07.013_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/add.14797","article-title":"Cost-effectiveness of expanding the capacity of opioid agonist treatment in Ukraine: dynamic modeling analysis","volume":"115","author":"Morozova","year":"2019","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.jval.2020.07.013_bib46","doi-asserted-by":"crossref","first-page":"E317","DOI":"10.1503\/cmaj.110669","article-title":"Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment","volume":"184","author":"Nosyk","year":"2012","journal-title":"Canadian Med Assoc J"},{"key":"10.1016\/j.jval.2020.07.013_bib47","doi-asserted-by":"crossref","first-page":"140","DOI":"10.34196\/ijm.00146","article-title":"Building a microsimulation model of\u00a0heroin use careers in Australia","volume":"9","author":"Ritter","year":"2016","journal-title":"International J Microsimulation"},{"issue":"6","key":"10.1016\/j.jval.2020.07.013_bib48","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s11606-011-1962-8","article-title":"Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care","volume":"27","author":"Schackman","year":"2012","journal-title":"J\u00a0Gen Intern Med"},{"issue":"8","key":"10.1016\/j.jval.2020.07.013_bib49","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1287\/mnsc.46.8.1013.12025","article-title":"Methadone maintenance and HIV prevention: a cost-effectiveness analysis","volume":"46","author":"Zaric","year":"2000","journal-title":"Management Sci"},{"issue":"11","key":"10.1016\/j.jval.2020.07.013_bib50","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/hec.999","article-title":"Benefits and costs of methadone treatment: results from a lifetime simulation model","volume":"14","author":"Zarkin","year":"2005","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2020.07.013_bib51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.drugalcdep.2018.08.003","article-title":"Cost-effectiveness of naloxone kits in secondary schools","volume":"192","author":"Cipriano","year":"2018","journal-title":"Drug Alcohol Depend"},{"issue":"8","key":"10.1016\/j.jval.2020.07.013_bib52","first-page":"1051","article-title":"Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal in Russian cities","volume":"16","author":"Coffin","year":"2013","journal-title":"J\u00a0Med Econ"},{"issue":"1","key":"10.1016\/j.jval.2020.07.013_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","article-title":"Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal","volume":"158","author":"Coffin","year":"2013","journal-title":"Annals Internal Med"},{"issue":"4","key":"10.1016\/j.jval.2020.07.013_bib54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jval.2017.07.014","article-title":"Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom","volume":"21","author":"Langham","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.07.013_bib55","article-title":"Cost-effectiveness analysis of alternative naloxone distribution strategies: first responder and lay distribution in the United States","volume":"75","author":"Townsend","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"3","key":"10.1016\/j.jval.2020.07.013_bib56","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/S2468-2667(17)30006-3","article-title":"Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study","volume":"2","author":"Uyei","year":"2017","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.jval.2020.07.013_bib57","series-title":"Applied Methods of Cost-Effectiveness Analysis in Health Care.","author":"Gray","year":"2011"},{"issue":"1","key":"10.1016\/j.jval.2020.07.013_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","article-title":"Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal","volume":"158","author":"Coffin","year":"2013","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jval.2020.07.013_bib59","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.disamonth.2018.12.002","article-title":"The value of harm reduction for injection drug use: a clinical and public health ethics analysis","volume":"65","author":"Vearrier","year":"2019","journal-title":"Dis Mon"},{"issue":"3","key":"10.1016\/j.jval.2020.07.013_bib60","first-page":"192","article-title":"Harm reduction strategies for the opiod crisis","volume":"79","author":"Castillo","year":"2018","journal-title":"N\u00a0C Med J"},{"issue":"1","key":"10.1016\/j.jval.2020.07.013_bib61","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-018-0276-0","article-title":"Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study","volume":"16","author":"Goldman","year":"2019","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.jval.2020.07.013_bib62","series-title":"Approval Letter; 2002","year":"2002"},{"key":"10.1016\/j.jval.2020.07.013_bib63","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"7-8","key":"10.1016\/j.jval.2020.07.013_bib64","first-page":"8","article-title":"Methadone treatment of opiate addiction: a systematic review of comparative studies","volume":"17","author":"Ali","year":"2017","journal-title":"Innov Clin Neurosci"},{"issue":"7410","key":"10.1016\/j.jval.2020.07.013_bib65","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/bmj.327.7410.310","article-title":"Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials","volume":"327","author":"Van den Brink","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jval.2020.07.013_bib66","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jsat.2006.04.007","article-title":"Controlled trial of prescribed heroin in the treatment of opioid addiction","volume":"31","author":"March","year":"2006","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.jval.2020.07.013_bib67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","article-title":"Heroin-assisted treatment for opioid dependence: randomised controlled trial","volume":"191","author":"Haasen","year":"2007","journal-title":"Br J Psychiatry"},{"issue":"10118","key":"10.1016\/j.jval.2020.07.013_bib68","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X: BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2020.07.013_bib69","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.jval.2020.07.013_bib70","series-title":"FDA issues warning letter for not including the most serious risks in advertisement for medication-assisted treatment drug [press release]","year":"2019"},{"key":"10.1016\/j.jval.2020.07.013_bib71","series-title":"FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence [press release]","year":"2018"},{"key":"10.1016\/j.jval.2020.07.013_bib72","series-title":"FDA approves first buprenorphine implant for treatment of opioid dependence [press release]","year":"2016"},{"key":"10.1016\/j.jval.2020.07.013_bib73","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","article-title":"Buprenorphine treatment formulations: preferences among persons in opioid withdrawal management","volume":"94","author":"Kenney","year":"2018","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.jval.2020.07.013_bib74","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jsat.2019.06.007","article-title":"Opioid users\u2019 willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder","volume":"104","author":"Tompkins","year":"2019","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.jval.2020.07.013_bib75","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2020.01.009","article-title":"Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders","volume":"111","author":"Saunders","year":"2020","journal-title":"J\u00a0Subst Abuse Treat"},{"key":"10.1016\/j.jval.2020.07.013_bib76","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/11314840-000000000-00000","article-title":"The role of patient preferences in cost-effectiveness analysis","volume":"27","author":"Brazier","year":"2009","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2020.07.013_bib77","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1472-6963-12-253","article-title":"A framework for assessing Health Economic Evaluation (HEE) quality appraisal instruments","volume":"12","author":"Langer","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jval.2020.07.013_bib78","series-title":"Provisional Drug Overdose Death Counts [press release]","year":"2020"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520343990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520343990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:21:54Z","timestamp":1761096114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520343990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1098301520343990"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.07.013","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation in Opioid Modeling: Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}